Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001919298 | SCV002187670 | uncertain significance | not provided | 2022-09-08 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The arginine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 1421963). This variant has not been reported in the literature in individuals affected with CEP250-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 1220 of the CEP250 protein (p.Gln1220Arg). |
Ambry Genetics | RCV004044140 | SCV004082140 | uncertain significance | not specified | 2023-07-31 | criteria provided, single submitter | clinical testing | The c.3659A>G (p.Q1220R) alteration is located in exon 27 (coding exon 24) of the CEP250 gene. This alteration results from a A to G substitution at nucleotide position 3659, causing the glutamine (Q) at amino acid position 1220 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |